Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model.

In this paper we present a model of the macrophage T lymphocyte interactions that generate an anti-tumor immune response. The model specifies i) induction of cytotoxic T lymphocytes, ii) antigen presentation by macrophages, which leads to iii) activation of helper T cells, and iv) production of lymphoid factors, which induce a) cytotoxic macrophages, b) T lymphocyte proliferation, and c) an inflammation reaction. Tumor escape mechanisms (suppression, antigenic heterogeneity) have been deliberately omitted from the model. This research combines hitherto unrelated or even contradictory data within the range of behavior of one model. In the model behavior, helper T cells play a crucial role: Tumors that differ minimally in antigenicity (i.e., helper reactivity) can differ markedly in rejectability. Immunization yields protection against tumor doses that would otherwise be lethal, because it increases the number of helper T cells. The magnitude of the cytotoxic effector cell response depends on the time at which helper T cells become activated: early helper activity steeply increases the magnitude of the immune response. The type of cytotoxic effector cells that eradicates the tumor depends on tumor antigenicity: lowly antigenic tumors are attacked mainly by macrophages, whereas large highly antigenic tumors can be eradicated by cytotoxic T lymphocytes only.

[1]  B. Schick,et al.  Tumor immunity in the peritoneal cavity. , 1980, Contemporary topics in immunobiology.

[2]  R. Furth,et al.  The Current View on the Origin of Pulmonary Macrophages , 1982 .

[3]  G. Currie Cancer and the Immune Response , 1980 .

[4]  C. Taswell,et al.  Quantitation and Cloning of Cytolytic T Lymphocytes and their Precursors , 1980, Immunological reviews.

[5]  P. Askenase,et al.  Delayed-type hypersensitivity: activation of mast cells by antigen-specific T-cell factors initiates the cascade of cellular interactions. , 1983, Immunology today.

[6]  A. Albert,et al.  Tumors and the immune system: the effects of a tumor growth modulator☆ , 1980 .

[7]  W. Den Otter,et al.  Natural cytotoxic macrophages in the peritoneal cavity of mice. , 1979, British Journal of Cancer.

[8]  T. Rème,et al.  Stimulator cell requirements for allospecific T cell subsets: specialized accessory cells are required to activate helper but not cytolytic T lymphocyte precursors. , 1983, Journal of immunology.

[9]  David,et al.  Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cells. , 1975, Journal of immunology.

[10]  M. Greene,et al.  Regulation of the immune response to tumor antigens. IX. In vitro Lyt-1+2- cell proliferative responses to cellbound or subcellular tumor antigen. , 1983, Journal of immunology.

[11]  R. Palacios Mechanism of T Cell Activation: Role and Functional Relationship of HLA‐DR Antigens and Interleukins , 1982, Immunological reviews.

[12]  H. Cantor,et al.  Functional subclasses of T lymphocytes bearing different Ly antigens. II. Cooperation between subclasses of Ly+ cells in the generation of killer activity. , 1975, The Journal of experimental medicine.

[13]  H. Kirchner,et al.  Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. , 1976, Journal of immunology.

[14]  I. Fidler,et al.  In vitro activation of mouse macrophages by rat lymphocyte mediators. , 1976, Journal of immunology.

[15]  S. Swain,et al.  Mouse T-lymphocyte subpopulations: relationships between function and Lyt antigen phenotype. , 1980, Immunology today.

[16]  Stephen J. Merrill,et al.  Foundations of the use of an enzyme-kinetic analogy in cell-mediated cytotoxicity☆ , 1982 .